SOLARIS PHARMA CORP
GenericsSOLARIS PHARMA CORP is a generic drug manufacturer focused on Dermatology, Oncology, Cardiovascular.
SOLARIS PHARMA CORP's Key Drugs
SOLARIS PHARMA CORP's core commercial portfolio centers on CLINDAMYCIN PHOSPHATE AND TRETINOIN, spanning Dermatology and Oncology — its most strategically important drugs approved in the last 15 years.
SOLARIS PHARMA CORP's Recent FDA Approvals
New NDA/BLA approvals for SOLARIS PHARMA CORP over the last two years — novel drugs only, excluding generics and label supplements.
SOLARIS PHARMA CORP's Therapeutic Areas
SOLARIS PHARMA CORP's approved drugs and pipeline span 4 therapeutic areas, led by Dermatology and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOLARIS PHARMA CORP's Top Competitors
SOLARIS PHARMA CORP's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOLARIS PHARMA CORP Pipeline Snapshot
Active clinical trials for SOLARIS PHARMA CORP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CLINDAMYCIN PHOSPHATE AND TRETINOIN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2006-07-28
- Latest
- 2025-12-18
- Applications
- 10